News|Articles|June 9, 2025
FSP Outsourcing in Clinical Research: Trends and Opportunities
Author(s)PPD
When drug developers choose the right outsourcing strategies in clinical research, they can gain significant benefits in terms of quality, efficiency, and operational success. In its third annual Functional Service Provider (FSP) Trends Report, Thermo Fisher Scientific’s clinical research business—PPD—gathered insights from 150 global biotech and pharma leaders to determine how FSP models help sponsors address common industry obstacles.
Trending on Applied Clinical Trials Online
1
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
2
ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps
3
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
4
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
5